315 results
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
7 May 24
Ligand Reports First Quarter 2024 Financial Results
4:03pm
12 weeks of treatment and affirmed VK2809's potent effect on liver fat, along with its favorable tolerability and safety profile. Viking plans … an update on the Phase 3 RAISE trial evaluating the safety and efficacy of IV ganaxolone in patients with refractory status epilepticus. The trial
8-K
EX-3.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
19 Apr 24
Amendments to Articles of Incorporation or Bylaws
4:06pm
or order of business for the meeting; (ii) rules and procedures for maintaining order at the meeting and the safety of those present (including
8-K
EX-99.1
fg8j9
27 Feb 24
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
7:24am
8-K/A
EX-99.1
6rli6bpiqbmbq 01uquu
9 Nov 23
Ligand Reports Third Quarter 2023 Financial Results
9:48pm
8-K
EX-99.1
vyplqtyz
8 Nov 23
Ligand Reports Third Quarter 2023 Financial Results
4:08pm
8-K
EX-10.1
owkyu
17 Oct 23
Entry into a Material Definitive Agreement
7:24pm
8-K
EX-99.1
o1gj1 vdk
8 Aug 23
Ligand Reports Second Quarter 2023 Financial Results
4:02pm
8-K
EX-99.1
v53wt4i
4 May 23
Ligand Reports First Quarter 2023 Financial Results
4:06pm
8-K
EX-99.1
nxi4ly8kibe8
7 Nov 22
Ligand Reports Third Quarter 2022 Financial Results
4:04pm
425
EX-99.1
jgm0mto3rhx
21 Jun 22
Business combination disclosure
8:00am
8-K
EX-99.1
hk94349b
21 Jun 22
Regulation FD Disclosure
6:19am